Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Income from Continuing Operations data on record, last reported at 122510000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 52.42% year-over-year to 122510000.0; the TTM value through Dec 2025 reached 464829000.0, down 56.27%, while the annual FY2025 figure was 465317000.0, 56.18% down from the prior year.
  • Income from Continuing Operations reached 122510000.0 in Q4 2025 per CRNX's latest filing, up from 130091000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 22888000.0 in Q1 2021 and bottomed at 130091000.0 in Q3 2025.
  • Average Income from Continuing Operations over 5 years is 62128350.0, with a median of 53412000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: fell 20.23% in 2023, then tumbled 69.33% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 30808000.0 in 2021, then tumbled by 48.18% to 45652000.0 in 2022, then dropped by 22.53% to 55936000.0 in 2023, then plummeted by 43.69% to 80377000.0 in 2024, then plummeted by 52.42% to 122510000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 122510000.0 in Q4 2025, 130091000.0 in Q3 2025, and 115657000.0 in Q2 2025.